Trial Profile
A Study to Assess the Incidence of Deep Vein Thrombosis (DVT) Following Prophylactic Intravenous Administration of Recombinant Human Antithrombin(rhAT) to Hereditary Antithrombin (AT) Deficient Patients in High Risk Situations.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Antithrombin alfa (Primary)
- Indications Deep vein thrombosis
- Focus Registrational; Therapeutic Use
- Sponsors rEVO Biologics
- 05 Nov 2010 New trial record.